Repligen (RGEN) has agreed to acquire BioLife Solutions in a roughly $1.5 billion deal, a move that immediately shifts investor focus to how a larger cell therapy footprint could influence the stock’s risk and reward profile.

See our latest analysis for Repligen.

Repligen’s share price has been volatile, with a 22.82% 90 day share price return and a 10.68% 30 day share price return contrasting with a decline of 14.76% year to date, while the 1 year total shareholder return of 19.60% hints at improving sentiment despite weak guidance earlier and today’s BioLife deal.

If you are comparing Repligen with other growth stories in the sector, it can help to cast a wider net and check out 41 healthcare AI stocks

Bulls see Repligen using BioLife to lean harder into higher margin cell therapy tools, while bears focus on integration risk and already rich expectations. Which of those stories shows up when you line the valuation up against the numbers?

Most Popular Narrative: 20.5% Undervalued

Compared with the last close at $140.09, the most followed narrative puts Repligen’s fair value at $176.11, framing today’s BioLife move against already optimistic long term expectations.

Strategic push into fast-growing modalities like cell therapy and ADCs, combined with continued innovation in filtration and PAT-enabled systems, is expected to enhance product mix toward higher-margin offerings and drive gross margin expansion over the next several years.

Read the complete narrative.

Want to see why this narrative still points to upside even after a $1.5b deal? The core thesis rests on a tightly modeled mix of revenue growth, higher margins, and a richer earnings profile that aims to justify a steep future earnings multiple.

Result: Fair Value of $176.11 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Repligen’s reliance on funding challenged biotech customers and exposure to softer gene therapy demand could still pressure the growth and margin story behind that fair value.

Find out about the key risks to this Repligen narrative.

Another View: What Repligen’s P/S Ratio Is Telling You

Repligen may screen as 20.5% undervalued on fair value estimates, but the current P/S of 10.4x is far higher than the US Life Sciences industry at 4x, the peer average at 3.6x, and even the fair ratio of 5.5x. That gap suggests investors are paying up heavily for the story. How comfortable are you with that valuation risk?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of optimism and caution around Repligen is clear, so it makes sense to review the key data points yourself and move quickly to shape your own view using the 4 key rewards.

Looking for more investment ideas beyond Repligen?

If Repligen has sharpened your focus on quality and risk, use the Simply Wall Street Screener to uncover other opportunities that might fit your style and goals.

• Target potential mispricing by scanning for companies that combine strong fundamentals with attractive valuations using the 47 high quality undervalued stocks.
• Prioritize resilience by reviewing companies that appear on the 82 resilient stocks with low risk scores to see which stocks may better match your comfort with volatility.
• Hunt for early opportunities by checking the screener containing 20 high quality undiscovered gems and see which under-the-radar stocks align with your thesis before the crowd notices.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.